Venture Firm CRV Raises $750 Million Fund to Lead Seed and Series A Rounds
- Menlo Times
- Aug 4
- 2 min read

CRV, one of the oldest Venture Capital firms operating since 1970, led by General Partners Brittany Walker, Caitlin Bolnick Rellas, James Green, Jon Auerbach, Max Gazor, Murat Bicer, Reid Christian, and Saar Gur, has announced CRV XX, a $750 million Seed and Series A fund focused on high-caliber early-stage technology companies. Some of their best investments include Doordash, Mercury, and Vercel.
CRV Ventures focuses on more than just long-term returns — success is measured by the daily impact and deep relationships with founders. Known for being the first call during both highs and lows, the firm builds trust through hands-on support and one-on-one engagement that helps guide companies through every stage of their journey.
CRV Ventures values long-term relationships with both LPs and founders, viewing trust as core to its identity. Decades-long partnerships reflect a deep commitment to meaningful engagement, which continues to drive lasting impact and mutual success. CRV raised its latest fund, CRV XX, in just four weeks despite ongoing economic uncertainty—demonstrating the strength of its focused strategy and deep relationships with trusted partners, even in volatile times.
CRV XX will continue backing early and Series A-stage companies across core focus areas like consumer and devtools, while embracing the evolving role of AI. Rather than viewing AI as a standalone category, CRV sees its integration across sectors—like in Outtake, a cyber agent startup that merges AI and security—as the future of foundational innovation.
CRV XX continues the firm’s legacy of backing exceptional founders early, including repeat entrepreneurs like Harjot Gill of CodeRabbit and rising stars like Paul Klein IV of Browserbase. Both companies, backed at the Series A stage, have shown rapid growth, with thousands of customers and strong early valuations—highlighting CRV’s focus on identifying and supporting high-impact talent from the start.
Comments